EvoGenix (ASX:EGX) has reported results on the development of its product OVP, for the treatment of bone loss. [ + ]

The research community has paid tribute to Justice John Lockhart, the chair of a recently concluded review of Australia's stem cell legislation, who died in Sydney on Friday after a brief illness. [ + ]

A team of scientists at the Weizmann Institute of Science in Israel, led by Professor Michal Schwartz of the Neurobiology Department, has come up with new findings that may have implications in delaying and slowing down cognitive deterioration in old age.

Six months from completing an 18-month collaboration with the US-based High Q Foundation, Sydney's Proteome Systems (ASX:PXL) has statistically validated some of the multiple biomarkers for the inherited neurodegenerative disorder Huntington's disease which it identified in an earlier smaller study. [ + ]

Perth based BioPharmica (ASX:BPH) has opened a share purchase plan to raise AUD$2.5 million to fund the development of its portfolio of biomedical research. [ + ]

Dr Stephen Nutt, based at the Walter and Eliza Hall Institute, and Dr Anthony Hannan, at the Howard Florey Institute, have each been awarded five-year grants of AUD$1 million under the Pfizer Australia Research Fellowship scheme. [ + ]

A group of entrepreneurial PhD students from a number of Melbourne's premier medical research facilities has developed an innovative biology experiment kit to promote science among school-aged children.

Melbourne's Antisense Therapeutics (ASX:ANP) has been granted approval to restart the phase IIa trial of its antisense compound ATL1102 for patients with relapsing remitting multiple sclerosis. [ + ]

Tissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has clarified aspects of its application for approval to market its ReCell product in Australia, following a decision by the Therapeutic Goods Administration (TGA) in December to reject approval for the product. [ + ]

Sydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, is to postpone its IPO on the Nasdaq national market. [ + ]

Consulting firm Innovation Dynamics has added a new string to its bow, after being granted an Australian Financial Services licence by ASIC. [ + ]

Cell therapy company Living Cell Technologies (ASX:LCT) has raised more than AUD$3 million through a placement of ordinary shares to US shareholders and an Australian investor. [ + ]

Researchers have begun trials which will allow radiation doses in computed tomography (CT) scans to be estimated much more accurately.

Anti-viral drug developer Narhex Life Sciences (ASX:NLS) has commenced recruitment of healthy volunteers for the phase I clinical trial of its anti-HIV protease inhibitor drug DG17. [ + ]

Artificial heart firm HeartWare (ASX:HTW) has been granted its first regulatory approval to commence human implants of the HVAD left ventricular assist device from the Austrian Ministry of Health. [ + ]